51
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      TOX transcriptionally and epigenetically programs CD8 + T cell exhaustion

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          SUMMARY

          Exhausted CD8 + T cells (T EX) in chronic infections and cancer have limited effector function, high inhibitory receptor co-expression and extensive transcriptional changes compared to effector (T EFF) or memory (T MEM) CD8 + T cells. T EX are important clinical targets of checkpoint blockade and other immunotherapies. Epigenetically, T EX are a distinct immune subset, with a unique chromatin landscape compared to T EFF and T MEM. However, the mechanisms governing the transcriptional and epigenetic development of T EX remain unknown. Here, we identify the HMG-box transcription factor TOX as a central regulator of T EX. TOX is largely dispensable for T EFF and T MEM formation, but is critical for exhaustion and without TOX T EX do not form. TOX is induced by calcineurin and NFAT2 and operates in a feed-forward loop to become calcineurin independent and sustained in T EX. Thus, robust TOX expression results in commitment to T EX by translating persistent stimulation into a distinct T EX transcriptional and epigenetic developmental program.

          Related collections

          Most cited references26

          • Record: found
          • Abstract: found
          • Article: not found

          Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade.

          Blocking Programmed Death-1 (PD-1) can reinvigorate exhausted CD8 T cells (TEX) and improve control of chronic infections and cancer. However, whether blocking PD-1 can reprogram TEX into durable memory T cells (TMEM) is unclear. We found that reinvigoration of TEX in mice by PD-L1 blockade caused minimal memory development. After blockade, reinvigorated TEX became reexhausted if antigen concentration remained high and failed to become TMEM upon antigen clearance. TEX acquired an epigenetic profile distinct from that of effector T cells (TEFF) and TMEM cells that was minimally remodeled after PD-L1 blockade. This finding suggests that TEX are a distinct lineage of CD8 T cells. Nevertheless, PD-1 pathway blockade resulted in transcriptional rewiring and reengagement of effector circuitry in the TEX epigenetic landscape. These data indicate that epigenetic fate inflexibility may limit current immunotherapies.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Immunogenetics. Chromatin state dynamics during blood formation.

            Chromatin modifications are crucial for development, yet little is known about their dynamics during differentiation. Hematopoiesis provides a well-defined model to study chromatin state dynamics; however, technical limitations impede profiling of homogeneous differentiation intermediates. We developed a high-sensitivity indexing-first chromatin immunoprecipitation approach to profile the dynamics of four chromatin modifications across 16 stages of hematopoietic differentiation. We identify 48,415 enhancer regions and characterize their dynamics. We find that lineage commitment involves de novo establishment of 17,035 lineage-specific enhancers. These enhancer repertoire expansions foreshadow transcriptional programs in differentiated cells. Combining our enhancer catalog with gene expression profiles, we elucidate the transcription factor network controlling chromatin dynamics and lineage specification in hematopoiesis. Together, our results provide a comprehensive model of chromatin dynamics during development. Copyright © 2014, American Association for the Advancement of Science.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains

              CRISPR-Cas9 genome editing technology holds great promise for discovering therapeutic targets in cancer and other diseases. Current screening strategies target CRISPR-induced mutations to the 5’ exons of candidate genes 1–5 , but this approach often produces in-frame variants that retain functionality, which can obscure even strong genetic dependencies. Here we overcome this limitation by targeting CRISPR mutagenesis to exons encoding functional protein domains. This generates a higher proportion of null mutations and substantially increases the potency of negative selection. We show that the magnitude of negative selection reports the functional importance of individual protein domains of interest. A screen of 192 chromatin regulatory domains in murine acute myeloid leukemia cells identifies six known drug targets and 19 additional dependencies. A broader application of this approach may allow comprehensive identification of protein domains that sustain cancer cells and are suitable for drug targeting.
                Bookmark

                Author and article information

                Journal
                0410462
                6011
                Nature
                Nature
                Nature
                0028-0836
                1476-4687
                7 July 2019
                17 June 2019
                July 2019
                17 December 2019
                : 571
                : 7764
                : 211-218
                Affiliations
                [1 ]Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA USA.
                [2 ]Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA USA.
                [3 ]Parker Institute for Cancer Immunotherapy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA USA.
                [4 ]Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA USA.
                [5 ]Epigenetics Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA USA.
                [6 ]Department of Cell and Developmental Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA USA.
                [7 ]Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA USA.
                [8 ]Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA USA.
                [9 ]Department of Medicine II, Gastroenterology, Hepatology, Endocrinology, and Infectious Diseases, University Medical Center Freiburg, Germany.
                [10 ]BIOSS Centre for Biological Signaling Studies, Freiburg, Germany,
                [11 ]Research Division of Immunology, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA USA.
                Author notes

                Contributions

                O.K. and E.J.W. conceived the project, designed experiments and wrote the manuscript. O.K. performed the majority of the experiments described herein and performed the in vitro, in vivo, and bioinformatics analysis. J.R.G. wrote the script to perform PSEA and, with S.M., performed pre-processing of RNA and ATAC-seq data. S.M. performed co-IP experiments for Western blot. S.F.N and K.P.P contributed to in vivo tumor and influenza experiments. M.T.W. performed IP experiments for mass spectrometry. A.C.H., P.Y., and S.M.G. acquired and stained human PBMC and TIL samples. J.E.W., R.P.S., and J.R.G. provided critical edits to the manuscript. All authors reviewed the manuscript.

                [*]

                Lead Contact: E. John Wherry

                Corresponding Author Correspondence to E. John Wherry ( wherry@ 123456pennmedicine.upenn.edu ).
                Article
                NIHMS1530609
                10.1038/s41586-019-1325-x
                6713202
                31207603
                698b0326-0513-4cce-a69b-ed36b8e44823

                No additional permissions are required for any of the photographs, images, or illustrations within any of the figures of this manuscript.

                Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

                History
                Categories
                Article

                Uncategorized
                Uncategorized

                Comments

                Comment on this article